Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

Thomas Yau; Yoon‐Koo Kang; Tae‐You Kim; Anthony B. El-Khoueiry; Armando Santoro; Bruno Sangro; Ignacio Melero; Masatoshi Kudo; Ming-Mo Hou; Ana Matilla; Francesco Tovoli; Jennifer J. Knox; Aiwu Ruth He; Bassel F. El‐Rayes; Mirelis Acosta-Rivera; Ho-Yeong Lim; Jaclyn Neely; Yun Shen; Tami Wisniewski; Jeffrey Anderson; Chiun Hsu

doi:10.1001/jamaoncol.2020.4564

Abstract

ClinicalTrials.gov Identifier: NCT01658878.

Keywords

MedicineNivolumabIpilimumabTolerabilityInternal medicineSorafenibHepatocellular carcinomaAdverse effectRandomized controlled trialSurgeryGastroenterologyOncologyCancerImmunotherapy

Affiliated Institutions

Related Publications

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn , Baek‐Yeol Ryoo , Philippe Merle +17 more

PURPOSE Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). K...

2019 Journal of Clinical Oncology 1737 citations

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu , Yoon‐Koo Kang , Chia‐Jui Yen +21 more

Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patien...

2019 The Lancet Oncology 1593 citations

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Richard S. Finn , Masafumi Ikeda , Andrew X. Zhu +17 more

PURPOSE The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with programmed death r...

2020 Journal of Clinical Oncology 1120 citations

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa , George Lau , Masatoshi Kudo +28 more

BACKGROUND: A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion reg...

2022 NEJM Evidence 1193 citations

Immunotherapies for hepatocellular carcinoma

Josep M. Llovet , Florian Castet , Mathias Heikenwälder +6 more

Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death and its incidence is increasing globally. Around 50% of patie...

2021 Nature Reviews Clinical Oncology 1590 citations

Publication Info

Year: 2020
Type: article
Volume: 6
Issue: 11
Pages: e204564-e204564
Citations: 1129
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1129

OpenAlex

Cite This

APA Style

                            
                                
                                    Thomas Yau, 
                                
                                    Yoon‐Koo Kang, 
                                
                                    Tae‐You Kim
                                
                                et al.
                            
                            (2020). 
                            Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib. 
                            JAMA Oncology
                            , 6
                            (11)
                            , e204564-e204564.
                            https://doi.org/10.1001/jamaoncol.2020.4564
                        

Identifiers

DOI: 10.1001/jamaoncol.2020.4564